Overall, the addition of PTCy to auto-HSCT represents a novel translational strategy with the potential to enhance immune resetting, suppress residual autoreactivity, and improve long-term remission rates in autoimmune disease patients.
Abstract
Autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as an effective therapeutic option for selected patients with severe autoimmune diseases, particularly relapsingremitting multiple sclerosis. However, disease relapse remains a significant challenge, suggesting the persistence of autoreactive lymphocytes and incomplete restoration of sustained immune tolerance. Post-transplant cyclophosphamide (PTCy) is widely employed following allogeneic HSCT for graftversus- host disease prophylaxis. Here, we propose that incorporation of PTCy into auto-HSCT protocols may further improve outcomes in selected autoimmune disease patients by reducing and suppressing residual autoreactive T cells that survive conditioning and subsequently undergo lymphopenia-driven and / or antigen-induced proliferation post-transplant. Drawing on mechanistic and clinical insights from allogeneic transplantation, we discuss how PTCy could augment depletion of pathogenic effector T cells while supporting hematopoietic recovery and immune reconstitution. Because complete removal of autoreactive lymphocyte populations is unlikely, long-term disease control will probably require promoting peripheral immune regulation. Multiple sclerosis is highlighted as a model disease, although the concepts discussed may extend to other autoimmune disorders. Overall, the addition of PTCy to auto-HSCT represents a novel translational strategy with the potential to enhance immune resetting, suppress residual autoreactivity, and improve long-term remission rates in autoimmune disease patients.
It was determined that PT-Cy-mediated T cell depletion also depleted pathogen-specific TCRs, rendering PT-Cy patients more likely to lack detectable graft-derived pathogen-specific TCRs early after transplant, which was associated with an increased risk of severe infection.
S. DeWolf, S. Siegel, Joseph Schmalz et al.· Science Translational Medici...· 0 citations
CD19-directed chimeric antigen receptor T cell therapy (CAR19) improves survival in relapsed/refractory large B cell lymphoma compared with immunochemotherapy with intent for autologous hematopoietic cell transplantation (autoHCT). However, major toxicities include prolonged cytopenias, infection and secondary hematolo...
M. Hamilton, Nick Phillips, T. Noordenbos et al.· Nature Genetics· 0 citations
Two solid organ transplant recipients treated with non-myeloablative conditioning followed by naïve T-cell-depleted hematopoietic stem cell transplantation and donor memory T-cell infusions use mixed lymphocyte reactions with TCRβ sequencing to track donor-reactive T-cell clonotypes to support minimization of immunosup...
A. Pérez-Martínez, C. Aguirre-Portolés, C. Mestre-Durán et al.· Communications Medicine· 0 citations
This review synthesizes contemporary breakthroughs in HSCT biology, technology, and clinical application, critically examines unresolved barriers, and highlights future directions, including Artificial Intelligence (AI)-driven predictive analytics, universal donor platforms, and equitable global access strategies.
M. Abah, Ovwigho Ugbede, O. C. et al.· DS Reviews of Research in Li...· 0 citations
Post-transplant cyclophosphamide (PTCy) is increasingly used for graft-versus-host disease (GVHD) prophylaxis in both HLA-matched (matched-PTCy) and haplotype-mismatched (haplo-PTCy) hematopoietic stem cell transplantation (HCT), but the effects of PTCy on immune reconstitution in different donor settings remain incomp...
Michela Ansuinelli, H. Kim, Francesco Malfona et al.· Blood Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.